Moomoo AI 已提取核心信息
Fortress Biotech, Inc., reported a completed transaction involving the acquisition of 2,101,496 shares of Avenue Therapeutics common stock on January 2, 2024. The shares were granted at no cost, as indicated by a transaction price of $0.00. Following this transaction, Fortress Biotech's direct holdings in Avenue Therapeutics increased to a total of 3,133,886 shares. The nature of the transaction was described as a grant, award, or other acquisition, according to the transaction code 'A'. This significant acquisition reflects changes in the ownership stake that Fortress Biotech, Inc. has in Avenue Therapeutics.
Fortress Biotech, Inc., reported a completed transaction involving the acquisition of 2,101,496 shares of Avenue Therapeutics common stock on January 2, 2024. The shares were granted at no cost, as indicated by a transaction price of $0.00. Following this transaction, Fortress Biotech's direct holdings in Avenue Therapeutics increased to a total of 3,133,886 shares. The nature of the transaction was described as a grant, award, or other acquisition, according to the transaction code 'A'. This significant acquisition reflects changes in the ownership stake that Fortress Biotech, Inc. has in Avenue Therapeutics.
Fortress Biotech, Inc. 报告称，2024年1月2日完成了一项交易，涉及收购2,101,496股Avenue Therapeutics普通股。这些股票是免费授予的，交易价格为0.00美元。在这笔交易之后，丰泽生物科技在Avenue Therapeutics的直接持股量增加到总共3,133,886股。根据交易代码 “A”，该交易的性质被描述为赠款、奖励或其他收购。这项重大收购反映了丰泽生物科技公司在Avenue Therapeutics的所有权的变化。
Fortress Biotech, Inc. 报告称，2024年1月2日完成了一项交易，涉及收购2,101,496股Avenue Therapeutics普通股。这些股票是免费授予的，交易价格为0.00美元。在这笔交易之后，丰泽生物科技在Avenue Therapeutics的直接持股量增加到总共3,133,886股。根据交易代码 “A”，该交易的性质被描述为赠款、奖励或其他收购。这项重大收购反映了丰泽生物科技公司在Avenue Therapeutics的所有权的变化。
有用
没用
